The Whole Slide Imaging Market is witnessing steady expansion as pathology departments move toward digital workflows. Whole slide imaging scanners capture complete tissue specimens at high resolution and convert conventional glass slides into digital files. These images can then be reviewed using specialized software, shared with healthcare professionals, incorporated into research databases, and analyzed using artificial intelligence. The technology is increasingly used across hospitals, diagnostic centers, academic institutions, and pharmaceutical companies.

According to Market Research Future, the global whole slide imaging market was valued at USD 1.38 billion in 2025 and is forecast to reach USD 2.67 billion by 2035. The market is expected to register a CAGR of 6.85% between 2026 and 2035. This growth reflects increasing investments in digital pathology infrastructure and the broader adoption of connected diagnostic technologies.

One of the most significant market trends is the increasing use of AI-enabled pathology. Digital slides provide the large datasets required to train and deploy image-analysis algorithms. AI applications can support pathologists by identifying suspicious areas, measuring tissue characteristics, quantifying biomarkers, and prioritizing cases. Such capabilities can help laboratories manage growing workloads while potentially improving diagnostic consistency.

The growing use of immunohistochemistry is another important development. Digital imaging allows laboratories and pharmaceutical companies to analyze stained tissue samples and support biomarker evaluation. Market Research Future identifies immunohistochemistry as the fastest-growing application segment, with a projected CAGR of 7.84% through 2035. This growth is closely associated with targeted therapies, oncology research, and companion diagnostic development.

Hospitals and clinical laboratories represent an important customer base because they process large volumes of pathology specimens. Digital workflows can simplify image access, facilitate remote consultations, and reduce dependence on physical slide transportation. Pharmaceutical and biotechnology companies are also expanding their use of whole slide imaging for clinical trials, drug discovery, and pathology-based research.

North America currently leads the market, accounting for approximately 46.8% of the market in 2025. Asia-Pacific is expected to record the strongest regional growth, supported by healthcare digitization and increasing demand for telepathology services.

Although implementation costs, data management, interoperability, and user training remain challenges, technological advances are improving the accessibility of digital pathology. As healthcare providers continue adopting AI, cloud platforms, and remote diagnostic solutions, whole slide imaging is expected to become increasingly integrated into routine pathology and research workflows.